KR100468648B1 - Ganoderma lucidum exo- and endo-biopolymer having a hypolipidemic effect and the use thereof - Google Patents

Abstract

The present invention relates to extracellular polysaccharides and intracellular polysaccharides derived from Ganoderma lucidum mushroom having hypolipidemic effect, oral administration of extracellular polysaccharides or intracellular polysaccharides produced from mycelium liquid culture of Ganoderma lucidum mushroom to hyperlipidemic rats Compared to the effect of increasing hypolipidemia is excellent. In addition, the present invention extracellular and intracellular polysaccharides not only reduce the concentration of total cholesterol, triglycerides, phospholipids, arteriosclerosis index and LDL cholesterol in plasma, but also reduce the total cholesterol, triglyceride and phospholipid concentrations in the liver. There is.

Description

Ganoderma lucidum exo- and endo-biopolymer having a hypolipidemic effect and the use about

The present invention relates to an extracellular polysaccharide and an intracellular polysaccharide derived from Ganoderma lucidum having an hypolipidemic effect. More specifically, the present invention is to separate the intracellular polysaccharides from the extracellular polysaccharides and mycelium produced by the mycelium liquid culture of Ganoderma lucidum having hypolipidemic effect in hyperlipidemic rats and the extracellular polysaccharide using the hypolipidemic activity of the substance and It relates to the use of intracellular polysaccharides.

Reshi of Ganoderma lucidum has been known as an important herbal medicine used to treat a number of diseases such as hepatitis, hypertension, hypercholesterolemia and gastric cancer in Korea, China, Japan, and the East. In addition, very interesting biological activities have recently been demonstrated, including anti-cancer, hypotension, hepatoprotective, anti-complementary, antimicrobial and anti-inflammatory effects.

Recently, attempts have been made to eliminate hyperlipidemia. It has been reported that lowering the concentration of circulating cholesterol can prevent, arrest and even reverse atherosclerosis of the heart. Currently, some drugs such as lovastatin and cholesterylamine have been used to lower serum cholesterol, but are too expensive and have side effects for large scale use. Therefore, in the field of nutritional research, research on natural substances is attempting to achieve the above object. Many edible mushrooms already have high content of high fiber, high protein, low fat and trace elements, which has proved to be an important natural therapy to control hyperlipidemia. However, although the hypolipidemic activity of many mushroom species has already been demonstrated, most early studies are limited to components isolated from fruiting bodies or cultured mycelia. On the other hand, there is relatively little research on the effects of extracellular polysaccharides produced in mycelial liquid culture of such mushrooms. Although Chung et al. Reported the hypoglycemic activity of Ganoderma lucidum fruiting body extract, no studies have reported the hypolipidemic activity of its liquid culture precipitate.

Accordingly, an object of the present invention is to provide an extracellular polysaccharide and an intracellular polysaccharide derived from Ganoderma lucidum having an hypolipidemic effect extracted from cultured mycelium produced in liquid culture, and a method for separating the same.

The object of the present invention is to culture the Ganoderma lucidum mycelium liquid, obtain extracellular polysaccharides from the culture medium and intracellular polysaccharides from the mycelium and orally administer the above-mentioned substances to hyperlipidemic rats to obtain blood and various organs from the mice. Blood was analyzed to examine the contents of total cholesterol, triglycerides, HDL (high concentration lipoprotein) cholesterol, phospholipids, LDL (low concentration lipoprotein) cholesterol, and arteriosclerosis index. Cholesterol, triglyceride and phospholipid concentrations were measured to investigate the hypolipidemic effect of extracellular and intracellular polysaccharides derived from Ganoderma lucidum.

Hereinafter, the configuration of the present invention will be described by examples.

1 is a diagram illustrating a process for separating extracellular and intracellular polysaccharides from mycelium liquid culture of Ganoderma lucidum of the present invention.

The present invention comprises the culture of mycelium liquid mycelium mushroom and the separation of extracellular and intracellular polysaccharide from the culture medium and the step of investigating the hypolipidemic effect of the polysaccharide in hyperlipidemic rats.

More specifically, the extracellular polysaccharide derived from Ganoderma lucidum of the present invention is obtained from the following steps:

A) Inoculate the Ganoderma lucidum culture in potato / dextrose broth (pH 4.5) and spawn on a rotary shaker at 30 ° C and 120 rpm.

B) After 7 days of the culture, the 50 mL of the culture solution was pulverized in a sterile state, and then the culture medium was prepared in advance (glucose 0.1%, sucrose 0.9%, yeast extract 0.05%, peptone 0.2%, potato) Dextrose broth 0.2%, NH ₄ H ₂ PO ₄ 0.05%, DL-serine 0.05%, KH ₂ PO ₄ 0.1%, CaCl ₂ 0.06%, MgSO ₄ 7H ₂ O 0.2%, FeSO ₄ 7H ₂ O 0.002%, ZnSO ₄ · 7H ₂ O 0.002%, MnSO ₄ · H ₂ O 0.002%, pH 4.5) inoculated at 1% (v / v),

C) culture the mycelia liquid for 18 days in a rotary shaker at 120 rpm, 30 ℃ condition containing the pulverized,

D) To the supernatant obtained by centrifuging the mycelium liquid culture solution at 10,447 x g for 20 minutes, ethanol was added at a ratio of 1: 4 and precipitated for one day, followed by centrifugation.

E) freeze-dried the precipitate obtained above, dissolve in distilled water at a rate of 10 mg / mL and centrifuged for 10,447 x g, 20 minutes,

F) obtained by dialysis of the supernatant obtained by centrifugation for 3 days and then lyophilization.

In addition, the intracellular polysaccharide derived from Ganoderma lucidum of the present invention is obtained from the following steps:

A) Inoculate the Ganoderma lucidum culture in potato / dextrose broth (pH 4.5) and spawn on a rotary shaker at 30 ° C and 120 rpm.

B) After 7 days of the culture, the 50 mL of the culture solution was pulverized in a sterile state, and then the culture medium was prepared in advance (glucose 0.1%, sucrose 0.9%, yeast extract 0.05%, peptone 0.2%, potato) Dextrose broth 0.2%, NH ₄ H ₂ PO ₄ 0.05%, DL-serine 0.05%, KH ₂ PO ₄ 0.1%, CaCl ₂ 0.06%, MgSO ₄ 7H ₂ O 0.2%, FeSO ₄ 7H ₂ O 0.002%, ZnSO ₄ · 7H ₂ O 0.002%, MnSO ₄ · H ₂ O 0.002%, pH 4.5) inoculated at 1% (v / v),

C) culture the mycelia liquid for 18 days in a rotary shaker at 120 rpm, 30 ℃ condition containing the pulverized,

D) The mycelium liquid culture solution was centrifuged at 10,447 x g for 20 minutes, and the mycelium obtained was washed three times with distilled water, followed by three times of hot water extraction for 2 hours, followed by centrifugation at 10,447 x g for 20 minutes.

E) freeze-dried the precipitate obtained above, dissolve in distilled water at a rate of 10 mg / mL and centrifuged for 10,447 x g, 20 minutes,

F) obtained by dialysis of the supernatant obtained by centrifugation for 3 days and then lyophilization.

In order to investigate the hypolipemia effect of the present invention Ganoderma lucidum-derived extracellular polysaccharide and intracellular polysaccharide obtained from the above separation method, experiments after oral administration of the extracellular polysaccharide or intracellular polysaccharide to diet-induced hyperlipidemic rats Obtaining blood and various organs from rats and analyzing the blood to investigate the contents of total cholesterol, triglycerides, HDL (high concentration lipoprotein) cholesterol, phospholipids, LDL (low concentration lipoprotein) cholesterol and atherosclerosis in plasma The weight of organs in mice and the total cholesterol, triglyceride, and phospholipid concentrations of livers were measured to investigate the hypolipidemic effect of extracellular and intracellular polysaccharides derived from Ganoderma lucidum.

The present invention isolates the intracellular polysaccharides as well as the extracellular polysaccharide derived from Ganoderma lucidum mushroom and compared the hypotensive effects of these substances.

The pharmaceutical composition may be prepared by mixing a composition for treating hyperlipidemia having an extracellular polysaccharide or an intracellular polysaccharide having an hypolipidemic effect derived from Ganoderma lucidum and an pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention may further include conventionally used excipients, disintegrants, sweeteners, glidants, anti-esthetics, etc., unit administration such as oral or parenteral formulations by conventional methods It may be formulated in a pharmaceutical form or in multiple dosage forms. The composition may be parenterally or orally administered as desired, and the extracellular polysaccharide derived from Ganoderma lucidum per kg body weight per day may be administered by dividing 0.05 to 0.2 g in 1 to several times. Dosage levels for a particular patient may vary depending on the particular compound to be used, body weight, patient's age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of disease, and the like.

Each data value shown in each example is shown in the table expressed as the average ± standard deviation. The mean of each group was compared by single variance analysis and Duncan's multiple-range test. Statistical difference considered p <0.05 as a significant value.

In addition, the ratio of the media component described in an Example and a claim means a percentage by weight.

Hereinafter, the specific method of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to these Examples.

EXAMPLE

Example 1 Isolation of Extracellular and Intracellular Polysaccharides from Mycelium Liquid Culture of Ganoderma Lucidum Mushroom

In order to separate the substance having hypolipidemic activity of the Ganoderma lucidum of the present invention, first, Ganoderma lucidum was mainly collected and separated from Gyeongbuk, South Korea, and the potato / dextrose broth in a rotary shaker at 30 ℃, 120 rpm conditions incubated at pH 4.5). After 7 days, 50 mL of the culture was crushed under sterile conditions and culture medium (galactose 0.1%, sucrose 0.9%, yeast extract 0.05%, peptone 0.2%, potato dextrose broth 0.2%, NH ₄ H ₂ PO ₄ 0.05%, DL-serine 0.05%, KH ₂ PO ₄ 0.1%, CaCl ₂ 0.06%, MgSO ₄ · 7H ₂ O 0.2%, FeSO ₄ · 7H ₂ O 0.002%, ZnSO ₄ · 7H ₂ O 0.002%, MnSO ₄ H ₂ O 0.002%, pH 4.5) at 1% (v / v). A 500-mL flask containing 200 mL of the medium was placed in a rotary shaker at 30 ° C. and 120 rpm and subjected to mycelial liquid culture for 18 days. The process of separating the extracellular polysaccharide from the liquid culture is shown in FIG.

According to Figure 1, in order to separate the extracellular polysaccharide derived from Ganoderma lucidum mushroom, the supernatant obtained by centrifuging the mycelium liquid culture medium cultured for 18 days at 10,447 xg for 20 minutes in a ratio of 1: 4 and precipitated for one day Then centrifuged. Thereafter, the precipitate obtained above was lyophilized and dissolved in distilled water at a rate of 10 mg / mL, followed by centrifugation for 10,447 xg for 20 minutes, and the supernatant obtained therefrom was dialyzed for 3 days, and then lyophilized. The derived extracellular polysaccharide was obtained.

In order to compare the hypolipidemic activity of the intracellular polysaccharides as well as the extracellular polysaccharides derived from Ganoderma lucidum of the present invention, the intracellular polysaccharides were isolated from mycelium after liquid culture of Ganoderma lucidum. First, the mycelium liquid culture medium cultured for 18 days was centrifuged at 10,447 x g for 20 minutes, and the mycelium obtained was washed three times with distilled water, extracted three times with hot water for 2 hours, and then centrifuged at 10,447 x g for 20 minutes. The supernatant obtained therefrom was added ethanol in a ratio of 1: 4, precipitated for one day, centrifuged, and the precipitate was lyophilized, and dissolved in distilled water at a rate of 10 mg / mL, followed by centrifugation at 10,447 x g for 20 minutes. The supernatant obtained after centrifugation was dialyzed for 3 days and then lyophilized to obtain intracellular polysaccharides derived from Ganoderma lucidum.

Example 2: Hypoglycemic Effects of Extracellular and Intracellular Polysaccharides from Ganoderma lucidum Mushroom

The extracellular polysaccharide or intracellular polysaccharide derived from Ganoderma lucidum of the present invention obtained in Example 1 was orally administered to diet-induced hyperlipidemic rats to examine the growth reaction and hypolipidemic effect of rats. First, Sprague-Dalley male rats (approximately 100-120 g) obtained from the Korea Advanced Institute of Chemical Technology were placed in stainless steel cages and kept at a constant temperature (22 ± 2 ℃) at a humidity (55 ± 5 ℃) and then cycled for 12 hours It was raised in a room with controlled contrast. A modified AIN-76 diet was fed to rats for 6 weeks. The diet consists of 55.5% carbohydrates (including 40.5% sucrose), 14.5% fat (30% of total energy) and 20% casein per weight, the components of which are shown in Table 1 . Subsequently, hyperlipidemia was induced by providing a high fat diet for 2 weeks, and then, according to the body weight, three of the four groups were classified as treatment groups. In each experimental group, extracellular or intracellular polysaccharides produced in mycelium liquid culture of Ganoderma lucidum mushroom were administered orally to rats daily for 4 weeks at a concentration of 100 mg / kg of saline (control) and 1 kg of body weight. Dietary intake and body weight were recorded daily and are shown in Table 3. At the end of the oral administration, the rats were fasted for 14 hours, followed by mild ether anesthesia, incised abdomen, and sacrificed immediately. After that, blood was obtained from the aorta.

In order to separate plasma and organs from the mice, the blood samples obtained above were placed in heparinized tubes and centrifuged for 1,100 × g, 10 minutes to separate plasma. Each organ was washed with 0.9% NaCl, separated and weighed. Cold saline was sparged in the liver, cut and frozen at -70 ° C.

Chemical analysis was performed on the plasma and liver obtained above. Plasma total cholesterol, triglycerides, phospholipids, and HDL cholesterol were measured using cholesterol oxidase-DAOS method, Bucolo method using glycerol kinase, choline oxidase method and tungstate phosphate-Mg precipitation method, respectively. Low concentration lipoprotein (LDL) cholesterol, arteriosclerosis index, and ratio of HDL cholesterol to total cholesterol (HTR) were calculated according to the following formula:

LDL cholesterol = total cholesterol-HDL cholesterol-(triglyceride / 5),

Arteriosclerosis index = (total cholesterol-HDL cholesterol) / HDL cholesterol,

HTR = HDL cholesterol / total cholesterol.

Liver lipids were extracted according to the method of Folch et al. Liver total cholesterol, triglyceride and phospholipid concentrations were analyzed according to the same method as plasma total cholesterol, triglycerides and phospholipids after treatment with Triton X-100.

Dietary Components of Rats Ingredient Composition ratio (%) Normal diet High fat diet Caseindextrin sucrose rod soybean oil AIN-synthetic mineral AIN-synthetic vitamin C α-cellulose 20.09.555.55.04.01.0-5.0 20.09.546.59.05.04.01.04.01.0

Experimental group to identify hypotensive activity group Oral administration Normal ¹⁾ Control ²⁾ Extracellular Polysaccharide ²⁾ Intrapolysaccharide ²⁾ None Extracellular polysaccharide obtained from mycelium liquid culture of 0.9% NaCl Ganoderma lucidum intracellular polysaccharide obtained from mycelium liquid culture of Ganoderma lucidum mushroom

¹⁾ 8 normal rats

^{2) Group of} 8 hyperlipidemic rats. Each group was orally administered saline (control), extracellular or intracellular polysaccharides at a concentration of 100 mg / kg body weight for 4 weeks every day.

Table 3 shows the effects of intracellular and extracellular polysaccharides on weight gain, dietary intake and dietary efficiency of the mycelium liquid cultures of Ganoderma lucidum.

Effects of Extracellular and Intracellular Polysaccharides from Ganoderma lucidum on Growth of Hyperlipidemic Rats County ¹⁾ Weight gain (g / day) Dietary Intake (g / day) Dietary efficiency ²⁾ Normal Control Extracellular Polysaccharide Intracellular Polysaccharide 7.54 ± 0.16 ^NS 7.13 ± 0.227.18 ± 0.127.26 ± 0.21 26.25 ± 0.6123.13 ± 0.8022.31 ± 0.4622.51 ± 0.34 0.30 ± 0.001 ^NS 0.31 ± 0.020.32 ± 0.010.32 ± 0.02

¹⁾ Same as Table 2

²⁾ weight gain / dietary intake

NS: no significance

Each value represents the mean ± standard deviation for 8 animals.

As shown in Table 3, for 4 weeks, all experimental groups remained healthy and showed normal weight. No significant difference in weight gain or dietary intake was observed in the experimental group administered extracellular or intracellular polysaccharides of Ganoderma lucidum. Similarly, there was no significant difference between the experimental groups in dietary efficiency.

The effects of intracellular and extracellular polysaccharides on the weight of various organs in the experimental group are shown in Table 4.

Effects of Extracellular and Intracellular Polysaccharides from Ganoderma lucidum on Weights of Various Organs in Hyperlipidemic Rats County ¹⁾ Liver (g / 100g body weight) Heart (g / 100g body weight) Height (g / 100g weight) Spleen (g / 100g weight) Normal Control Extracellular Polysaccharide Intracellular Polysaccharide 3.62 ± 0.14 ^a 5.28 ± 0.10 ^c 4.64 ± 0.14 ^b 4.83 ± 0.12 ^bc 0.33 ± 0.01 ^NS 0.29 ± 0.010.30 ± 0.010.30 ± 0.01 0.75 ± 0.06 ^NS 0.66 ± 0.010.65 ± 0.020.65 ± 0.02 0.18 ± 0.01 ^NS 0.15 ± 0.000.17 ± 0.010.16 ± 0.01

¹⁾ Same as Table 2

^NS : no significance

Each value represents the mean ± standard deviation for 8 animals.

^{a, b, c} : p <0.05 was significantly different between the experimental groups.

As shown in Table 4, the weights of heart, kidney and spleen were not significantly different among the experimental groups. However, liver weights were very low in the group receiving extracellular polysaccharides compared to the control group. The increase in liver weight in hyperlipidemic rats is due to the accumulation of lipid content in liver tissue. Shen et al. And Dietschy et al. Have shown that in dietary hyperlipidemic animals, the concentration of LDL cholesterol in plasma decreases, resulting in inappropriate lipid metabolism that improves the concentration of acetyl CoA in the liver and eventually participates in lipogenesis. It is reported to accumulate in lipids.

In this example, oral administration of intracellular and extracellular polysaccharides did not cause any changes to the overall behavior of the animals and there were no dead animals. Thus, even after oral administration of intracellular and extracellular polysaccharides of Ganoderma lucidum, no adverse effects were observed in rats.

Effects of Extracellular and Intracellular Polysaccharides from Ganoderma Lucidum on Plasma Total Cholesterol, LDL Cholesterol, Triglycerides and Phospholipids in Hyperlipidemic Rats County ¹⁾ Total cholesterol (mg / dl) LDL cholesterol ²⁾ (mg / dl) Triglycerides (mg / dl) Phospholipids (mg / dl) Normal Control Extracellular Polysaccharide Intracellular Polysaccharide 90.62 ± 3.84 ^a 143.26 ± 7.26 ^d 98.86 ± 3.89 ^ab 120.10 ± 1.27 ^c 59.99 ± 3.24 ^a 115.70 ± 4.12 ^d 70.56 ± 3.17 ^b 93.06 ± 2.89 ^c 31.50 ± 3.12 ^a 59.94 ± 4.68 ^c 38.74 ± 3.05 ^ab 43.77 ± 2.93 ^b 89.03 ± 6.11 ^a 131.36 ± 6.76 ^c 94.40 ± 2.49 ^ab 103.58 ± 3.57 ^b

¹⁾ Same as Table 2.

²⁾ Total Cholesterol-HDL Cholesterol- (Triglycerides / 5)

Each value represents the mean ± standard deviation for 8 animals.

^{a, b, c, d} : It showed a significant difference of p <0.05 between each experimental group.

As shown in Table 5, plasma total cholesterol, LDL cholesterol, triglyceride and phospholipid concentrations were significantly reduced compared to the control group in rats treated with extracellular or intracellular polysaccharides. However, extracellular polysaccharides had stronger hypolipidemic activity than intracellular polysaccharides and lowered the total cholesterol, LDL cholesterol, triglyceride and phospholipid concentrations of plasma to 31.0, 39.0, 35.4 and 28.1%, respectively.

Effect of Extracellular and Intracellular Polysaccharides from Ganoderma Lucidum on HDL Cholesterol Ratio (HTR) on Plasma HDL Cholesterol, Atherosclerosis Index and Total Cholesterol in Hyperlipidemic Rats County ¹⁾ HDL cholesterol (mg / dl) Arteriosclerosis index ²⁾ HTR ³⁾ Normal Control Extracellular Polysaccharide Intracellular Polysaccharide 24.33 ± 1.38 ^c 15.57 ± 1.21 ^a 20.55 ± 1.07 ^bc 18.29 ± 1.16 ^b 2.72 ± 0.03 ^a 8.20 ± 0.32 ^d 3.81 ± 0.13 ^b 5.57 ± 0.26 ^c 0.27 ± 0.01 ^c 0.11 ± 0.00 ^a 0.21 ± 0.01 ^b 0.15 ± 0.01 ^ab

¹⁾ Same as Table 2.

²⁾ (Total Cholesterol-HDL Cholesterol) / HDL Cholesterol

³⁾ HDL cholesterol / total cholesterol

Each value represents the mean ± standard deviation for 8 animals.

^{a, b, c, d} : It showed a significant difference of p <0.05 between each experimental group.

As shown in Table 6, HDL cholesterol concentration, arteriosclerosis index and HTR in plasma were significantly increased in the experimental group administered with extracellular or intracellular polysaccharides, and the extracellular polysaccharides proved more effective. Extracellular polysaccharides actually increased plasma HDL cholesterol and HTR to 24.2% and 47.6% and decreased arteriosclerosis index to 53.5% compared to the control group.

The effects of extracellular and intracellular polysaccharides of Ganoderma lucidum on hepatic lipids are shown in Table 7.

Effects of Extracellular and Intracellular Polysaccharides from Ganoderma lucidum on Liver Cholesterol, Triglycerides and Phospholipids in Hyperlipidemic Rats County ¹⁾ Total cholesterol (mg / g) Triglycerides (mg / g) Phospholipids (mg / g) Normal Control Extracellular Polysaccharide Intracellular Polysaccharide 1.84 ± 0.04 ^a 5.77 ± 0.22 ^c 4.48 ± 0.24 ^b 4.89 ± 0.13 ^bc 7.82 ± 0.78 ^a 19.25 ± 2.05 ^bc 14.81 ± 1.47 ^b 17.64 ± 0.92 ^b 7.11 ± 0.18 ^a 9.32 ± 0.13 ^c 8.12 ± 0.19 ^ab 8.67 ± 0.26 ^b

¹⁾ Same as Table 2.

^NS : no significance

Each value represents the standard ± standard deviation for 8 animals.

^{a, b, c} : p <0.05 was significantly different between the experimental groups.

As shown in Table 7, the total cholesterol, triglyceride, and phospholipid concentrations of the liver were significantly reduced to 22.4%, 23.1%, and 12.9% in the experimental group to which the extracellular polysaccharide was administered. In 15.3%, 8.4% and 7.0%.

As is currently known, the risk of atherosclerosis is more dependent on the LDL concentration of plasma than on the total cholesterol concentration in the body. One interesting dermatological finding recently demonstrated that the concentration of HDL is inversely proportional to the risk of atherosclerosis. In other words, a significant reduction in LDL and total cholesterol in plasma reduces the production of total cholesterol in liver tissue and can effectively remove LDL cholesterol without subsequent regeneration in various tissues. Therefore, this results in a decrease in the lipid concentration of liver tissue when the extracellular polysaccharide and the intracellular polysaccharide in this embodiment is in agreement with the above proposal. Presumably, extracellular and intracellular polysaccharides would have been achieved by controlling lipid metabolism in liver tissue.

Through this example, although the exact mechanism of the hypolipidemic effect of extracellular polysaccharide of Ganoderma lucidum is still unclear, inhibition of absorption and biosynthesis of cholesterol, inhibition of biosynthesis of LDL precursor ultra low concentration lipoprotein, promotion of LDL conversion and secretion of bile acids Likewise, the possibility of the associated effect of extracellular polysaccharides on hyperlipidemia cannot be ruled out. Therefore, it would be necessary to investigate the exact mechanism of the hypolipidemic effect and to investigate the chemical and pharmaceutical investigation to separate the active source to be useful for prophylactic therapeutic purposes in alleviating hyperlipidemia.

As described above, the present invention, as described through the examples, the extracellular polysaccharide or intracellular polysaccharide produced from the mycelium liquid culture of the Ganoderma lucidum mushroom of the present invention orally administered to hyperlipidemic rats excellent effect that the hypolipemia effect compared to the control group It works. In addition, the present invention extracellular and intracellular polysaccharides not only reduce the concentration of total cholesterol, triglycerides, phospholipids, arteriosclerosis index and LDL cholesterol in plasma, but also reduce the total cholesterol, triglyceride and phospholipid concentrations in the liver. There is. Therefore, the extracellular polysaccharide or intracellular polysaccharide derived from Ganoderma lucidum of the present invention has a hypolipemia effect, and therefore, it is possible to provide a composition for treating hyperlipidemia using the polysaccharide as an active ingredient, which is a very useful invention in the pharmaceutical industry.

Claims (5)

delete A) Inoculate the Ganoderma lucidum culture in potato / dextrose broth (pH 4.5) and spawn on a rotary shaker at 30 ° C and 120 rpm. B) After 7 days of the culture, the 50 mL of the culture solution was pulverized in a sterile state, and then the culture medium was prepared in advance (glucose 0.1%, sucrose 0.9%, yeast extract 0.05%, peptone 0.2%, potato) Dextrose broth 0.2%, NH ₄ H ₂ PO ₄ 0.05%, DL-serine 0.05%, KH ₂ PO ₄ 0.1%, CaCl ₂ 0.06%, MgSO ₄ 7H ₂ O 0.2%, FeSO ₄ 7H ₂ O 0.002%, ZnSO ₄ · 7H ₂ O 0.002%, MnSO ₄ · H ₂ O 0.002%, pH 4.5) inoculated at 1% (v / v), C) culture the mycelia liquid for 18 days in a rotary shaker at 120 rpm, 30 ℃ condition containing the pulverized, D) To the supernatant obtained by centrifuging the mycelium liquid culture solution at 10,447 x g for 20 minutes, ethanol was added at a ratio of 1: 4 and precipitated for one day, followed by centrifugation. E) freeze-dried the precipitate obtained above, dissolve in distilled water at a rate of 10 mg / mL and centrifuged for 10,447 x g, 20 minutes, F) The supernatant obtained by centrifugation is separated by extracellular polysaccharide separation method in mycelium liquid culture of Ganoderma lucidum mushroom, which is obtained by dialysis for 3 days and then lyophilized. Total cholesterol, LDL cholesterol, and triglycol in the plasma of animals Extracellular derivatives from Ganoderma lucidum activity with hypolipidemic activity, which are characterized by decreasing ceride, phospholipids and atherosclerosis index and liver cholesterol and triglyceride and phospholipid concentrations and increasing the ratio of HDL cholesterol to total cholesterol in plasma Polysaccharide. delete A) Inoculate the Ganoderma lucidum culture in potato / dextrose broth (pH 4.5) and spawn on a rotary shaker at 30 ° C and 120 rpm. B) After 7 days of the culture, the 50 mL of the culture solution was pulverized in a sterile state, and then the culture medium was prepared in advance (glucose 0.1%, sucrose 0.9%, yeast extract 0.05%, peptone 0.2%, potato) Dextrose broth 0.2%, NH ₄ H ₂ PO ₄ 0.05%, DL-serine 0.05%, KH ₂ PO ₄ 0.1%, CaCl ₂ 0.06%, MgSO ₄ 7H ₂ O 0.2%, FeSO ₄ 7H ₂ O 0.002%, ZnSO ₄ · 7H ₂ O 0.002%, MnSO ₄ · H ₂ O 0.002%, pH 4.5) inoculated at 1% (v / v), C) culture the mycelia liquid for 18 days in a rotary shaker at 120 rpm, 30 ℃ condition containing the pulverized, D) The mycelium liquid culture solution was centrifuged at 10,447 x g for 20 minutes, and the mycelium obtained was washed three times with distilled water, followed by three times of hot water extraction for 2 hours, followed by centrifugation at 10,447 x g for 20 minutes. E) freeze-dried the precipitate obtained above, dissolve in distilled water at a rate of 10 mg / mL and centrifuged for 10,447 x g, 20 minutes, F) the supernatant obtained by centrifugation for 3 days, followed by dialysis and lyophilization, and is isolated by the method for separating intracellular polysaccharides derived from Ganoderma lucidum mycelium. Total cholesterol, LDL cholesterol, triglycerides, Intracellular polysaccharide derived from Ganoderma lucidum mycelium with hypolipidemic activity characterized by reducing phospholipids and arteriosclerosis index and liver cholesterol and triglyceride and phospholipid concentrations and increasing plasma HDL cholesterol and HDL cholesterol ratio to total cholesterol . The composition for treating hyperlipidemia comprising an extracellular polysaccharide derived from Ganoderma lucidum having hypolipidemic activity according to claim 2 or an intracellular polysaccharide derived from Ganoderma lucidum having hypolipidemic activity according to claim 4 as an active ingredient.